3-[(4-fluorophenyl)ethyl]aniline | 1310581-34-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-[(4-fluorophenyl)ethyl]aniline
• 英文别名: 3-[2-(4-fluorophenyl)ethyl]aniline
• CAS: 1310581-34-0
• 化学式: C₁₄H₁₄FN
• 分子量: 215.27
• InChiKey: QRCBAOGEROMRAO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  四氯苯二甲酸酐 、 3-[(4-fluorophenyl)ethyl]aniline 反应 1.0h， 以88%的产率得到4,5,6,7-tetrachloro-N-{3-[2-(4-fluorophenyl)ethyl]phenyl}phthalimide
  参考文献：
  名称：

  Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists

  摘要：

  Novel dipeptidyl peptidase IV (DPP-IV) inhibitors with a phenethylphenylphthalimide skeleton were prepared based on alpha-glucosidase inhibitors and liver X receptor (LXR) antagonists derived from thalidomide. Representative compounds showed non-competitive inhibition of DPP-IV and 28a exhibited 10-fold selectivity for DPP-IV over DPP-8. Compound 28a is the first non-competitive, selective DPP-IV inhibitor. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.026
• 作为产物：
  描述：

  1-fluoro-4-[2-(3-nitrophenyl)ethenyl]benzene 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙酸乙酯 为溶剂， 以90%的产率得到3-[(4-fluorophenyl)ethyl]aniline
  参考文献：
  名称：

  Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists

  摘要：

  Novel dipeptidyl peptidase IV (DPP-IV) inhibitors with a phenethylphenylphthalimide skeleton were prepared based on alpha-glucosidase inhibitors and liver X receptor (LXR) antagonists derived from thalidomide. Representative compounds showed non-competitive inhibition of DPP-IV and 28a exhibited 10-fold selectivity for DPP-IV over DPP-8. Compound 28a is the first non-competitive, selective DPP-IV inhibitor. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.026

文献信息

• [EN] METALLOENZYME INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE MÉTALLOENZYMES
  申请人：VPS 3 INC

  公开号：WO2018165520A1

  公开（公告）日：2018-09-13

  Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.

  提供具有HDAC6调节活性的化合物，以及通过HDAC6介导的治疗疾病、疾病或症状的方法。
• Synthesis and Biological Evaluation of Direct Thrombin Inhibitors Bearing 4-(Piperidin-1-yl)pyridine at the P1 Position with Potent Anticoagulant Activity
  作者：Modesto de Candia、Filomena Fiorella、Gianfranco Lopopolo、Andrea Carotti、Maria Rosaria Romano、Marcello Diego Lograno、Sophie Martel、Pierre-Alain Carrupt、Benny D. Belviso、Rocco Caliandro、Cosimo Altomare

  DOI：10.1021/jm401169a

  日期：2013.11.14

  (fIIa) and factor Xa (fXa) inhibition activities, anti-fIIa activity and artificial membrane permeability were considerably improved by optimizing the basic P1 and the X-substituted phenyl P4 binding moieties. Structure–activity relationship studies, usefully complemented with molecular modeling results, led us to identify compound 13b, which showed excellent fIIa inhibition (Ki = 6 nM), weak anti-Xa

  描述了一种新型的非肽类直接凝血酶抑制剂的设计和合成，该抑制剂建立在1-（吡啶-4-基）哌啶-4-羧酰胺的结构上。从显示弱的凝血酶（fIIa）和Xa因子（fXa）抑制活性的强碱性1- ami基哌啶衍生物（6）开始，通过优化碱性P1和X-取代的苯基P4可显着提高抗fIIa活性和人工膜通透性结合部分。结构-活性关系研究以及有用的分子建模结果使我们得以鉴定出化合物13b，该化合物表现出出色的fIIa抑制作用（K i = 6 nM），抗Xa活性弱（K i= 5.64μM），并且对其他丝氨酸蛋白酶（例如胰蛋白酶）具有显着的选择性。化合物13b在低微摩尔范围内显示出体外抗凝活性，并具有显着的膜通透性。在小鼠中（离体），13b在口服给药（100 mg·kg –1）后2 h表现出抗凝作用，与对照组相比，活化的部分凝血活酶时间（aPTT）延长了43％（P <0.05）。
• BECKER, RAINER;WRIEDE, ULRICH;SCHIRMER, ULRICH;PARD, ADOLF;WUERZER, BRUNO+
  作者：BECKER, RAINER、WRIEDE, ULRICH、SCHIRMER, ULRICH、PARD, ADOLF、WUERZER, BRUNO+

  DOI：——

  日期：——
• Non-competitive and selective dipeptidyl peptidase IV inhibitors with phenethylphenylphthalimide skeleton derived from thalidomide-related α-glucosidase inhibitors and liver X receptor antagonists
  作者：Kazunori Motoshima、Kazuyuki Sugita、Yuichi Hashimoto、Minoru Ishikawa

  DOI：10.1016/j.bmcl.2011.03.026

  日期：2011.5

  Novel dipeptidyl peptidase IV (DPP-IV) inhibitors with a phenethylphenylphthalimide skeleton were prepared based on alpha-glucosidase inhibitors and liver X receptor (LXR) antagonists derived from thalidomide. Representative compounds showed non-competitive inhibition of DPP-IV and 28a exhibited 10-fold selectivity for DPP-IV over DPP-8. Compound 28a is the first non-competitive, selective DPP-IV inhibitor. (C) 2011 Elsevier Ltd. All rights reserved.